[A20-16] Niraparib (ovarian cancer) - Addendum to Commission A19-88
Last updated 02.04.2020
Project no.:
A20-16
Commission:
Commission awarded on 24.03.2020 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Cancer
Maintenance treatment of platinum-sensitive relapsed high-grade serous ovarian, fallopian tube, or primary peritoneal cancer with complete or partial response to platinum-based chemotherapy
The data subsequently submitted have changed the conclusion of the assessment: now hint of lesser benefit
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
| Project no. | Title | Status |
|---|---|---|
| A19-88 | Niraparib (ovarian cancer) - Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2020-04-02 A G-BA decision was published.